Psychotic symptoms following consumption of energy drinks: a systematic review
Abstract
Abstract Introduction Energy drinks (EDs) is an umbrella term for a family of beverages which contain high dosages of caffeine. ED consumption is increasing worldwide, and it is possible that excess ED consumption can cause or worsen symptoms of severe mental disorders (SMD) such as schizophrenia and bipolar affective disorder. Methods We searched three electronic databases for studies on patients with SMD who had experienced psychotic symptoms following the consumption of energy drinks, as well as patients who developed psychotic symptoms after ED consumption without any prior severe psychiatric disorder. We conducted and reported this systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We assessed the included case reports with the CARE criteria. Results We included 11 publications, all of which were case reports. Two of these described two patients with a primary diagnosis of schizophrenia and three described six patients with a primary diagnosis of bipolar disorder. The remaining eight case reports described eight patients with no prior psychiatric diagnosis. All had experienced deterioration or onset of psychotic symptoms following intake of EDs. Discussion ED use may be an emerging clinical challenge in psychiatry. However, it is also possible that EDs are simply a surrogate which indicate the occurrence of other factors associated with psychosis, such as male sex and poor socioeconomic status. Overall,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.